CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system to combat cancer by targeting the human poliovirus receptor. The project aims to advance this therapy through clinical trials, potentially improving outcomes for patients with solid tumors.
Nectin Therapeutics (NectinTx) is a venture-backed company with a top-notch team focused on innovative therapeutic options for cancer patients.
To address the limitations of available therapies, the company has developed a diverse pipeline of antibodies that overcome immune inhibitory pathways deployed by the tumours. NTX1088 is a monoclonal antibody that binds human poliovirus receptor (PVR) and activates patients immune system to fight cancer through a triple mechanism of action never demonstr…
NECTIN THERAPEUTICS LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
